LSLeonardo L. Seidl

Leonardo L. Seidl

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Leonardo L. Seidl has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comprehensive synthesis of K48/K63 ubiquitin pentamers by graph-empowered automation

    by Sohei Majima, Eric Kummelstedt, Toshiki Mikami, Leonardo Seidl, Jiling Han, Jeffrey Bode

    Linear, branched, and heterotypic ubiquitin (Ub) chains regulate essential cellular processes, yet their structural and functional analysis remains limited by the difficulty of preparing defined, homogeneous samples by chemical synthesis or biochemical assembly. We established a fully automated platform for the comprehensive synthesis of all 56 K48/K63-linked Ub tetramers and pentamers. This is achieved by iterative cycles of K48 or K63-specific chemoenzymatic conjugations of chemically synthesized Ub monomers bearing a new, fast-cleaving lysine protecting group compatible with folded proteins. A graph-based digital encoding of the Ub chain topologies enabled systematic enumeration and filtering of reaction pathways, guiding the selection of viable synthetic routes. This computational system generates reagent maps and executable code to direct iterative cycles of deprotection and conjugation on a standard, laboratory liquid handling robot. All 14 Ub tetramers and 42 Ub pentamers were obtained with high fidelity, as validated by SDS-PAGE and mass spectrometry. This work establishes a general framework for automated protein conjugate synthesis and provides on-demand access to the complete space of K48/K63 branched ubiquitin chains for biological and structural studies.

  • Open Access

    The indole motif is essential for the antitrypanosomal activity of N5-substituted paullones

    by Irina Ihnatenko, Marco J. Müller, Oliver C. F. Orban, Jens C. Lindhof, Diego Benítez, Cecilia Ortíz, Estefanía Dibello, Leonardo L. Seidl, Marcelo A. Comini, Conrad Kunick

    Severe infections with potentially fatal outcomes are caused by parasites from the genera Trypanosoma and Leishmania (class Kinetoplastea). The diseases affect people of remote areas in the tropics and subtropics with limited access to adequate health care. Besides insufficient diagnostics, treatment options are limited, with tenuous developments in recent years. Therefore, new antitrypanosomal antiinfectives are required to fight these maladies. In the presented approach, new compounds were developed and tested on the target trypanothione synthetase (TryS). This enzyme is crucial to the kinetoplastids’ unique trypanothione-based thiol redox metabolism and thus for pathogen survival. Preceding studies have shown that N5-substituted paullones display antitrypanosomal activity as well as TryS inhibition. Herein, this compound class was further examined regarding the structure-activity relationships (SAR). Diverse benzazepinone derivatives were designed and tested in cell-based assays on bloodstream Trypanosoma brucei brucei (T. b. brucei) and intracellular amastigotes of Leishmania infantum (L. infantum) as well as in enzyme-based assays on L. infantum TryS (LiTryS) and T. b. brucei TryS (TbTryS). While an exchange of just the substituent in the 9-position of paullones led to potent inhibitors on LiTryS and T. b. brucei parasites, new compounds lacking the indole moiety showed a total loss of activity in both assays. Conclusively, the indole as part of the paullone structure is pivotal for keeping the TryS inhibitory and antitrypanosomal activity of this substance class.


  • Open Access

    Discovery of Antitrypanosomal Indolylacetamides by a Deconstruction–Optimization Strategy Applied to Paullones

    by Jens C. Lindhof, Irina Ihnatenko, Marco J. Müller, Oliver C. F. Orban, Cecilia Ortíz, Diego Benítez, Estefanía Dibello, Leonardo L. Seidl, Marcelo A. Comini, Conrad Kunick

    The parasitic kinetoplastid diseases Leishmaniasis, Chagas disease and Human African Trypanosomiasis constitute serious threats for populations throughout the (sub‐)tropics. Most available drugs to treat these diseases possess inadequate properties and candidates to fill the drug pipeline are urgently needed. Paullone‐N5‐acetamides inhibit trypanothione synthetase (TryS), an essential kinetoplastid enzyme, and exhibit antiparasitic activity in the low micromolar range, but lack the desired selectivity against mammalian cells (selectivity index (SI):25).